It was agreed by the Heads of Medicines Agencies (HMA) in
Reykjavik on 28 February 2005 that by an agreed end-2009 deadline, the European
regulatory agencies must have the infrastructure and processes in place to
handle electronic-only eCTD submissions to successfully support the related
decision-making processes for the authorisation of medicinal products within the
European Union.
The IMB has fully adopted the European Guidance for eCTD
(electronic Common Technical Document) and NeeS (Non-eCTD electronic
submissions). The transition to electronic submissions brings with it several
advantages, not only the obvious reduction in printing, archiving and
transportation costs, but also facilitates consistency in information viewed
across agencies, the ability to manage the lifecycle of the product, and
improved navigation and assessment of documentation.
To find more information to use the below mentioned
weblink
No comments:
Post a Comment